Orion Eyes US Market For Phase III ALS Therapy
Oral Levosimendan May Improve Respiratory Symptoms
Sales grew but operating profits remained flat in 2019 at Orion Group, as the European mid-sized pharma pursued R&D in amyotrophic lateral sclerosis and cancer.
